Posted by Nicholas DiFranco | 08/30/2023

Extended-release tablets, also known as sustained-release, controlled-release, or time-release tablets, have become increasingly important in the healthcare sector due to their ability to maintain consistent drug levels in the body over a specific period. This drug delivery system provides various benefits, including enhanced patient compliance, minimized side effects, and improved therapeutic efficacy.

Categories: Pharmaceuticals

Posted by Ashley Rezak | 08/23/2023

While advancements in drug delivery are continually improving drug efficacy and bioavailability, there are still significant areas of unmet need in the market. This post discusses some key challenges of oral drug formulations and why they are important to address for patient health and differentiation in a crowded market. We uncover strategies for overcoming these challenges, including extended drug release, taste masking, and tablet size reduction.

Categories: Pharmaceuticals

Posted by Ashley Rezak | 08/01/2023

Topical drug delivery is a desirable option for formulators seeking a non-invasive, patient-preferred route of administration.

Categories: Pharmaceuticals

Posted by Joey Glassco | 06/29/2023

It’s no secret that solubility and bioavailability issues continue to challenge formulators and drug developers.

Categories: Pharmaceuticals

Posted by LLS Health Technical Team | 03/17/2023

The FDA 505(b)(2) regulatory pathway for drug approval, which allows applicants to use existing safety data as evidence, continues to grow in popularity.

Categories: Pharmaceuticals, Regulatory

Posted by Nicholas DiFranco | 01/25/2023

For drug developers working on oral solid dosage drug projects, solubility, and therefore bioavailability, is a significant challenge. At present, poor water solubility impacts around 40% of drugs currently on the market. 

Categories: Pharmaceuticals

Posted by LLS Health Technical Team | 05/03/2022

Apisolex™ technology provides formulators with a safe, polyamino-acid-based excipient to enhance the solubility of BCS Class II and IV APIs, including oncology agents, for parenteral delivery.

Categories: Pharmaceuticals, News

Posted by LLS Health Technical Team | 04/14/2022

Oral solid dosage forms, such as tablets, represent the largest segment of the pharmaceutical market. Despite the long history of oral solids in pharmaceuticals, there is still high demand for innovation. For new oral drugs to be commercially successful, it is key that they are easy to manufacture, cost-effective, and patient-friendly. Excipient technologies, such as Carbopol® polymers, can enable for formulator- and patient-centric benefits for these products. Learn more in this article. 

Categories: Pharmaceuticals

Posted by LLS Health Technical Team | 03/29/2022

Excipient-enabled approaches to solubility enhancement can accelerate drug development by leveraging established, scalable manufacturing techniques. In this post, we discuss common formulation tactics for BCS Class II and IV APIs and introduce Lubrizol’s novel solubility-enhancing excipients, oral-grade Apinovex™ polymer and injectable-grade Apisolex™ polymer.  

Categories: Pharmaceuticals

Posted by LLS Health Technical Team | 01/31/2022

In this post Lubrizol Life Science Health explores the regulatory requirements governing excipient safety for the United States as an example of best practice to help formulators understand how to select the most appropriate carbomer for their needs.

Categories: Pharmaceuticals, Regulatory, Carbomers